Piraeus Bank Group: 9M 2017 Financial Results
Key Highlights for the nine months ended 30 September 2017
Improving operating profitability & strengthened financial profile
- Core banking income, comprising NII and fees, at €558mn in Q3,+5% yoy
- Operating costs at €288mn in Q3, -4% yoy
- Cost to income ratio at 49% in Q3 from 55% a year ago
- Pre provision income at €294mn in Q3, +22% yoy
- Robust capital position maintained, phased-in CET-1 at 17.0% and fully-loaded at 16.6%
NPEs, NPLs down for 8 th consecutive quarter, best-in-class performance
- NPE operational target attained seamlessly for 5 quarters
- NPE stock down to €33.8bn, -€4bn from peak
- NPE formation at -€0.3bn, NPL formation at -€0.5bn, both pre-write offs
- NPL stock down to €22.1bn, -€6bn from peak
Increased deposit inflows, decreased eurosystem reliance
- Deposits in Greece +€0.9bn in Q3
- Loans to deposits ratio at 109%; 2nd best domestic market level
- ELA below €6bn in late November; 2nd best domestic market level
- Successful issue of 5Y €0.5bn covered bond in Oct.17
Significant progress towards successful implementation of “agenda 2020”
- Piraeus Core Bank €311mn net profit in 9Μ, RoA 1.1%, NIM at 309bps
- Marginally negative bottom-line on a Group level driven by continuous, intense clean-up
- New loan generation slightly up for SMEs, aiming at >€1bn new loans in 2018
“Following a period of uncertainty in the beginning of the year, the Greek economy is now back on track. The main indicators in key sectors of the economy are returning to positive territory and sentiment is improving. These developments are gradually feeding into the banking market.
In-line with our commitment to meet the NPEs targets agreed with our supervisory authorities, we outperformed market trends in both NPEs and NPLs reduction. In Q3 NPEs decreased by €0.7bn qoq and by €3.9bn from their peak in Sep.15. Pre write-off NPE formation was negative by -€0.3bn in Q3, the best quarterly performance for Piraeus to-date. NPLs decreased by €0.9bn qoq, down €5.8bn from the Sep.15 peak, reducing drastically the domestic NPL ratio from 40% to 36%. Pre write-off Q3.17 NPL formation was also negative by approximately -€0.5bn in Q3.
The positive trend in domestic customer deposits accelerated in Q3.17, with a quarterly increase of €0.9bn. ELA reliance decreased by €2.5bn in Q3.17 to €7.8bn, reduced further to below €6bn in late November, driven by additional deposit inflows and a more active interbank repo market. Piraeus’ ELA over assets and net loan-to-deposit ratios in Greece are both second best in the market.
Piraeus’ pre-provision income rose by 16% yoy in 9M.17 landing at €844mn, driven by a balanced 5% annual income growth and 5% cost reduction. The core sources of banking revenues, net interest and fee income, recorded a strong increase in Q3 of 5% versus the same period of last year. Our accelerated cost efficiency actions have driven cost-to-income ratio in Greece for 9M.17 to 48% from 54% in 9M.16. As we intensified our efforts to deal with legacy issues, provisions remained elevated, resulting in a marginal 9M.17 bottom-line loss for continuing operations of -€19mn. At the end of Sep.17, the Group’s phased-in and fully-loaded CET-1 capital ratios, both increased qoq, for the 2nd consecutive quarter, to 17.0% and 16.6%, respectively.
The Bank’s transformation journey is progressing with speed and we are focused on the disciplined execution of our strategic plan, “Agenda 2020”, aiming at aggressive balance sheet de-risking and rapid normalisation. Piraeus Core Bank recorded a net profit of €311mn in 9M.17, and a return on assets of 1.1%, highlighting the strength and profitability potential of our business once the Group’s transformation is completed. Piraeus Core Bank delivered a solid set of metrics in 9M.17, including NIM of 309bps and fees over assets of 87bps. “Piraeus Legacy Unit” (“PLU”) continued to contract RWAs by €0.6bn qoq. In the past few months, we have accelerated the pace of our non-core assets disposal program and we are actively contemplating inorganic balance sheet normalisation initiatives, in-line with our de-risking strategy.
The Bank’s reinvigorated management team, including our new Head of PLU, George Georgakopoulos, is working relentlessly towards the implementation of our plan, delivering on commitments and operational targets, while accelerating the clean-up of our balance sheet. We have already started the process for two NPE disposal transactions, one for business and one for consumer loans, of a total NPE on balance sheet amount of c. €2bn. For the full year 2017, we are committed to the accomplishment of our NPE goals, and are targeting a positive bottom-line result.”
Christos Megalou, Chief Executive Officer
Head of Press Office
+30 210 3288830
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13 | Pressemelding
Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21 | Pressemelding
Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38 | Pressemelding
A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00 | Pressemelding
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a
AML BitCoin Enters Phase II of ICO15.12.2017 09:00 | Pressemelding
NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom